Steady state investigation of possible pharmacokinetic interactions of moxonidine and glibenclamide.
The aim of the study presented here was to determine possible pharmacokinetic interactions of moxonidine and glibenclamide at steady state in 18 healthy male volunteers. Multiple oral doses of 0.2 mg of moxonidine b.i.d. (q. 12 h) and of 2.5 mg of glibenclamide o.i.d. (q. 24 h) were administered alone and in combination in an open, non-randomized, three-treatment design. The preparations were given for 5 days in each of the 3 periods. The results of this multiple dose study did not indicate substantial pharmacokinetic interactions of the drugs. Regarding the influence of glibenclamide on the pharmacokinetics of moxonidine, no significant changes were seen at all. In the presence of moxonidine, a minor decrease of bioavailability of glibenclamide was detectable, as could be derived from the AUC and clearance data. The actual differences were small and not considered to be of clinical significance.
Müller
M
M
L.A.B. GmbH & Co, Neu-Ulm, Germany.
Weimann
H J
HJ
Eden
G
G
Weber
W
W
Michaelis
K
K
Dilger
C
C
Achtert
G
G
D000284:Administration, Oral; D000328:Adult; D000959:Antihypertensive Agents / Q000493:pharmacokinetics*; D004347:Drug Interactions; D005905:Glyburide / Q000008:administration & dosage / Q000493:pharmacokinetics*; D006801:Humans; D007093:Imidazoles / Q000008:administration & dosage / Q000493:pharmacokinetics*; D008297:Male; D008875:Middle Aged
D000959:Antihypertensive Agents; D007093:Imidazoles; C043482:moxonidine; D005905:Glyburide